Overview

This trial is active, not recruiting.

Condition hepatitis e
Treatments hepatitis e vaccine, hepatitis b vaccine
Phase phase 3
Sponsor Xiamen University
Collaborator Xiamen Innovax Biotech Co., Ltd
Start date August 2007
End date June 2017
Trial size 112604 participants
Trial identifier NCT01014845, 2006AA02A209, Pro-HE-003

Summary

The primary purpose of this study is to determine whether the preventive hepatitis E are effective in the prevention of hepatitis E occurring at least 30 days after the administration of the third dose of vaccine.

The secondary purpose of this study is to to evaluate the safety and immunogenicity and immunopersistence of the study vaccine.

The initial study is planed to be ended on month 19 and the results were analysed and used for registration purpose. The extended study will be continued to assess the long-term efficacy, immunogenicity and safety.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose prevention
Arm
(Experimental)
Hepatitis E vaccine, containing 30mcg of HEV239 recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
hepatitis e vaccine Hecolin
Intramuscularly given at 0, 1, 6m for three doses.
(Placebo Comparator)
Hepatitis B vaccine, containing 5mcg of HBsAg recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
hepatitis b vaccine
Intramuscularly given at 0, 1, 6m for three doses.

Primary Outcomes

Measure
Rate of confirmed hepatitis E cases
time frame: One year since one month post the third injection

Secondary Outcomes

Measure
IgG anti-HEV seroconversion rate
time frame: On one month post the third injection
Persistency of IgG anti-HEV
time frame: One year

Eligibility Criteria

Male or female participants from 16 years up to 65 years old.

Inclusion Criteria: - Healthy people aged from 16 years to 65 years old at the time of the first vaccination, normal intelligence and agree to sign the informed consent form. - Subjects will reside in the study region in the next 19 months. - Free of history of hepatitis B or hepatitis E. - Can comply with the request of study. - Axillary temperature is below 37 degree centigrade. Exclusion Criteria: For dose 1: - Having other vaccine or immunoglobulin within two weeks; - Having allergic history to vaccine and medicine - Eclampsia, epilepsy, encephalopathy and history of mental disease or family; - Thrombocytopenia or other disturbance of blood coagulation which would lead to muscle injection taboo; - Fixed or suspected deficiency of immunologic function, containing immunosuppressant treatment(radiation therapy, chemical treatment, steroid hormone, antimetabolites, cytotoxic drugs), genetic defect(e.g. fabism), HIV or other factors; - congenital malformation, eccyliosis or severe chronic disease(e.g. Down Syndrome, diabetes, sickle cell anemia or mental disease); - fixed or suspected other disease including fever, active infection, liver and kidney disease, angiocardiopathy, malignancy, acute and chronic disease; - joining other clinical study undergoing; - women pregnant or in lactation. For dose 2 or 3: - Severe allergy for dose 1 or 2; - Severe adverse reaction associated with last vaccination; - New occurrence of symptoms meet dose 1 exclusion criteria after the first dose.

Additional Information

Official title A Phase 3, Randomized, Double-blind, Placebo (Hepatitis B Vaccine) Controlled Clinical Trial of Recombinant (E. Coli) Hepatitis E Vaccine
Principal investigator Feng-Cai Zhu, M.D.
Description Participants were randomly allocated into two groups, one received Hepatitis E vaccine and the other received hepatitis B vaccine. The study was carried out with two stages. In the first stage (phase 3a), 2 645 subjects was enrolled and actively monitored for solicited adverse events for 1 month after each injection. Serum samples from all the subjects were collected on day 0, 7m, 13m, 19m and timely after then to evaluate the immunogenicity and immuno-persistency. In the second stage (phase 3b), another 109 959 subjects was enrolled and monitored for solicited adverse events for 1 month after each injection. Serum samples from 9764 subjects among the phase 3b participants were collected on day 0, 7m, 19m and timely after then to evaluate the immunogenicity and immuno-persistency. Serious adverse events during the trial were followed up. Suspected hepatitis cases were identified through an established active hepatitis surveillance system. The sentinels of the system comprised all the healthcare facilities in the field. Suspected hepatitis was defined as when patients presented with systemic symptoms such as fatigue and/or loss of appetite for more than 3 days with alanine aminotransferase (ALT) exceeding 2.5 fold upper limit of normal range (ULN). Paired sera were obtained from these patients at the time of presentation and 2-6 weeks later. Sera were tested for the HEV antibodies and HEV-RNA.
Trial information was received from ClinicalTrials.gov and was last updated in January 2016.
Information provided to ClinicalTrials.gov by Xiamen University.